Kasai Hidenori, Allen Jeremy T, Mason Roger M, Kamimura Takashi, Zhang Zhi
Teijin Biomedical Laboratory, Medical Research Council Technology, 1-3 Burtonhole Lane, London, NW7 1AD, UK.
Respir Res. 2005 Jun 9;6(1):56. doi: 10.1186/1465-9921-6-56.
Fibroblastic foci are characteristic features in lung parenchyma of patients with idiopathic pulmonary fibrosis (IPF). They comprise aggregates of mesenchymal cells which underlie sites of unresolved epithelial injury and are associated with progression of fibrosis. However, the cellular origins of these mesenchymal phenotypes remain unclear. We examined whether the potent fibrogenic cytokine TGF-beta1 could induce epithelial mesenchymal transition (EMT) in the human alveolar epithelial cell line, A549, and investigated the signaling pathway of TGF-beta1-mediated EMT.
A549 cells were examined for evidence of EMT after treatment with TGF-beta1. EMT was assessed by: morphology under phase-contrast microscopy; Western analysis of cell lysates for expression of mesenchymal phenotypic markers including fibronectin EDA (Fn-EDA), and expression of epithelial phenotypic markers including E-cadherin (E-cad). Markers of fibrogenesis, including collagens and connective tissue growth factor (CTGF) were also evaluated by measuring mRNA level using RT-PCR, and protein by immunofluorescence or Western blotting. Signaling pathways for EMT were characterized by Western analysis of cell lysates using monoclonal antibodies to detect phosphorylated Erk1/2 and Smad2 after TGF-beta1 treatment in the presence or absence of MEK inhibitors. The role of Smad2 in TGF-beta1-mediated EMT was investigated using siRNA.
The data showed that TGF-beta1, but not TNF-alpha or IL-1beta, induced A549 cells with an alveolar epithelial type II cell phenotype to undergo EMT in a time-and concentration-dependent manner. The process of EMT was accompanied by morphological alteration and expression of the fibroblast phenotypic markers Fn-EDA and vimentin, concomitant with a downregulation of the epithelial phenotype marker E-cad. Furthermore, cells that had undergone EMT showed enhanced expression of markers of fibrogenesis including collagens type I and III and CTGF. MMP-2 expression was also evidenced. TGF-beta1-induced EMT occurred through phosphorylation of Smad2 and was inhibited by Smad2 gene silencing; MEK inhibitors failed to attenuate either EMT-associated Smad2 phosphorylation or the observed phenotypic changes.
Our study shows that TGF-beta1 induces A549 alveolar epithelial cells to undergo EMT via Smad2 activation. Our data support the concept of EMT in lung epithelial cells, and suggest the need for further studies to investigate the phenomenon.
成纤维细胞灶是特发性肺纤维化(IPF)患者肺实质的特征性表现。它们由间充质细胞聚集而成,这些间充质细胞位于未解决的上皮损伤部位,并与纤维化进展相关。然而,这些间充质表型的细胞起源仍不清楚。我们研究了强效促纤维化细胞因子转化生长因子β1(TGF-β1)是否能诱导人肺泡上皮细胞系A549发生上皮-间质转化(EMT),并研究了TGF-β1介导EMT的信号通路。
用TGF-β1处理A549细胞后,检测其EMT证据。通过以下方法评估EMT:相差显微镜下观察形态;对细胞裂解物进行蛋白质印迹分析,检测包括纤连蛋白EDA(Fn-EDA)在内的间充质表型标志物的表达,以及包括E-钙黏蛋白(E-cad)在内的上皮表型标志物的表达。还通过逆转录-聚合酶链反应(RT-PCR)测量mRNA水平,以及通过免疫荧光或蛋白质印迹检测蛋白质,来评估包括胶原蛋白和结缔组织生长因子(CTGF)在内的纤维化标志物。在有或没有MEK抑制剂的情况下,用单克隆抗体对细胞裂解物进行蛋白质印迹分析,以检测TGF-β1处理后磷酸化的细胞外信号调节激酶1/2(Erk1/2)和Smad2,从而表征EMT的信号通路。使用小干扰RNA(siRNA)研究Smad2在TGF-β1介导的EMT中的作用。
数据显示,TGF-β1而非肿瘤坏死因子-α(TNF-α)或白细胞介素-1β(IL-1β)能以时间和浓度依赖性方式诱导具有肺泡II型上皮细胞表型的A549细胞发生EMT。EMT过程伴随着形态改变以及成纤维细胞表型标志物Fn-EDA和波形蛋白的表达,同时上皮表型标志物E-cad表达下调。此外,发生EMT的细胞显示出包括I型和III型胶原蛋白以及CTGF在内的纤维化标志物表达增强。还证实了基质金属蛋白酶-2(MMP-2)的表达。TGF-β1诱导的EMT通过Smad2磷酸化发生,并且被Smad2基因沉默所抑制;MEK抑制剂未能减弱与EMT相关的Smad2磷酸化或所观察到的表型变化。
我们的研究表明,TGF-β1通过激活Smad2诱导A549肺泡上皮细胞发生EMT。我们的数据支持肺上皮细胞中EMT的概念,并表明需要进一步研究来探究这一现象。